Premium
Selective Targeting of Tumor and Stromal Cells By a Nanocarrier System Displaying Lipidated Cathepsin B Inhibitor
Author(s) -
Mikhaylov G.,
Klimpel D.,
Schaschke N.,
Mikac U.,
Vizovisek M.,
Fonovic M.,
Turk V.,
Turk Boris,
Vasiljeva Olga
Publication year - 2014
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201402305
Subject(s) - cathepsin b , internalization , nanocarriers , ex vivo , stromal cell , cancer research , in vivo , cathepsin , chemistry , drug , pharmacology , biology , biochemistry , cell , enzyme , microbiology and biotechnology
Cathepsin B (CtsB) is a lysosomal cysteine proteinase that is specifically translocated to the extracellular milieu during cancer progression. The development of a lipidated CtsB inhibitor incorporated into the envelope of a liposomal nanocarrier (LNC‐NS‐629) is described. Ex vivo and in vivo studies confirmed selective targeting and internalization of LNC‐NS‐629 by tumor and stromal cells, thus validating CtsB targeting as a highly promising approach to cancer diagnosis and treatment.